Skip to content

Author

Elnaz Aledavood

We have 3 of 13 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Aug 2026

Screening of candidate antiparasitic drugs against Sparicotyle chrysophrii: A phenotypic drug discovery approach.

Sparicotyle chrysophrii is a blood-feeding ectoparasite that poses a significant threat to the farming of gilthead seabream (Sparus aurata), a species of high economic relevance in Mediterranean aquaculture. There is an urgent need for effective, safe, and practical antiparasitic treatments to control these infections....

Ana León, Teresa Pirollo, Elnaz Aledavood et al. · 0 citations
Open access Jul 2026

AI-assisted fragment-based drug discovery of SARS-CoV-2 macrodomain binders validated by NMR and X-ray crystallography.

This study demonstrates the advantages of integrating AI with FBDD to streamline molecular design, providing a data-driven framework for discovering new Mac1 inhibitors and guiding future antiviral drug development.

Elnaz Aledavood, Sandra Ramos-Inza, Jannis Born et al. · 0 citations
Open access Jul 2026

Selective Brain-Penetrant TTBK1 Inhibitors Modulate TDP-43 Pathology and Rescue Cognitive Deficits in a Mouse Model of TDP-43 Proteinopathy

It is found that these inhibitors reduce TDP-43 phosphorylation levels in neuroblastoma cells and FTD patient-derived models, and restores cognitive deficits, conferred neuroprotection in the frontal cortex, and reduced microglial activation in an FTD-TDP mouse model, supporting its therapeutic potential.

Cecilia Sanchez-Santos, Alberto Jiménez-Amor, Loreto Martínez-González et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.